Wellpoint’s agency well-visit
This article was originally published in The Tan Sheet
FDA still is "actively working on" Wellpoint Health Network's petition to forcibly switch all low- and non-sedating antihistamines from prescription status, FDA promises the insurer in an Aug. 5 letter. Wellpoint urged Acting FDA Commissioner Lester Crawford, PhD, to reply to its 1998 and 2000 petitions to switch Pfizer's Zyrtec, Schering-Plough's Clarinex and Aventis' Allegra over the counter in a recent letter (1"The Tan Sheet" July 26, 2004, p. 6)...
You may also be interested in...
WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.
Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.